Rheumatoid neutrophilic dermatosis under treatment with the interleukin‐6‐receptor‐antagonist sarilumab in a patient with seropositive rheumatoid arthritis

Skin manifestations may arise as adverse events following the use of novel drugs. We report a case of a patient with seropositive rheumatoid arthritis who developed a rheumatoid neutrophilic dermatosis (RND) under treatment with the interleukin‐6‐receptor‐antagonist sarilumab. The skin lesions devel...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cutaneous pathology 2023-08, Vol.50 (8), p.734-738
Main Authors: Jost, Marion, Schwarz, Thomas, Wehkamp, Ulrike, Bohne, Ann‐Sophie, Drerup, Katharina
Format: Article
Language:English
Subjects:
Arthritis, Rheumatoid - drug therapy
Case reports
Dermatitis - pathology
Humans
IL‐6
Interleukin 6
Leukocytes (neutrophilic)
neutrophils
Nodules
Rheumatoid arthritis
RND
Skin Diseases
Skin lesions
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Skin manifestations may arise as adverse events following the use of novel drugs. We report a case of a patient with seropositive rheumatoid arthritis who developed a rheumatoid neutrophilic dermatosis (RND) under treatment with the interleukin‐6‐receptor‐antagonist sarilumab. The skin lesions developed 2–3 days after the first injection. RND presents with asymptomatic, symmetrical fixed urticarial‐like papules, plaques, and nodules, localized typically on the extensor surfaces of the forearms and hands. After discontinuing the medication, the nodules in our patient disappeared within a month.
ISSN:0303-6987
1600-0560
DOI:10.1111/cup.14425